[1]张 振,郜文辉,王亚琪,等.益气化瘀解毒方加减联合索拉非尼治疗原发性肝癌疗效研究*[J].陕西中医,2019,(3):322-324.
　ZHANG Zhen,GAO Wenhui,WANG Yaqi,et al.Study on curative effect of Yiqi Huayu Jiedu decoction combined with solafenil in the treatment of primary hepatocellular carcinoma[J].,2019,(3):322-324.
点击复制

益气化瘀解毒方加减联合索拉非尼治疗原发性肝癌疗效研究*
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2019年3
页码:
322-324
栏目:
临床研究
出版日期:
2019-03-05

文章信息/Info

Title:
Study on curative effect of Yiqi Huayu Jiedu decoction combined with solafenil in the treatment of primary hepatocellular carcinoma
文章编号:
DOI: 10.3969/j.issn.10007369.2019.03.014
作者:
张 振1; 2; 郜文辉2; 王亚琪1; 2; 李克雄1; 2; 曾普华1; 2
1.湖南省中医药研究院中医肿瘤研究所（长沙 410006）;2.湖南中医药大学中医学院（长沙 410007）;〖JZ〗3.抗肿瘤中药创制技术湖南省工程研究中心（长沙410006）
Author(s):
ZHANG Zhen; GAO Wenhui; WANG Yaqi; et al.
Institute of Traditional Clinese Medicine Oncology,Hunan Academy of Traditional Chinese Medicine (Changsha 410006)
关键词:
肝肿瘤; 中西医结合疗法; 益气化瘀解毒方; 疗效比较研究; 索拉非尼; 生存率
Keywords:
Key words Liver neoplasms; Integrated Chinese traditional and western medicine therapy; Yiqi Huayu Jiedu decoction; Comparative effectiveness research; Solafenil; Survival rate
分类号:
R735.7
文献标志码:
A
摘要:
摘 要 目的：比较索拉非尼与益气化瘀解毒方联合索拉非尼治疗原发性肝癌的临床疗效。方法：将56例原发性肝癌患者随机分为对照组和联合组，对照组予以索拉非尼口服，联合组在口服索拉非尼的基础上予以益气化瘀解毒方治疗。结果：两组患者基线资料比较无统计学意义（P＞0.05）。两组患者半年、1年、两年生存率分别是：对照组与联合组，78.6%与96.4%，60.7%与85.7%，14.3%与39.3%，差异具有统计学意义（P＜0.05）。患者两组PFS比较，对照组（4.55±0.41）个月，联合组（6.99±0.60）个月，差异具有统计学意义（P＜0.05）；两组患者生活质量评分，治疗前对照组与联合组无统计学意义，治疗后对照组高于联合组，且差异具有统计学意义。两组患者不良反应率比较，对照组与联合组无统计学意义。结论：尽管益气化瘀解毒方加减未能减轻索拉非尼毒副作用，但益气化瘀解毒方联合索拉非尼能延长患者半年、一年及两年生存率，同时能延长患者疾病无进展生存时间，改善患者生活质量。
Abstract:
Abstract Objective: Compare the clinical effect of Solafenib and Yiqi Huayu Jiedu decoction combined with Solafenil in the treatment of primary liver cancer. Methods: 56 patients with primary liver cancer were randomly divided into control group and combined group. The control group was given solafenil orally, and the combined group was treated with Yiqi Huayu Jiedu prescription on the basis of oral solafenil. Results: there was no significant difference in baseline between the two groups (P＞0.05). The half year, one year and two year survival rates of the two groups were 78.6% VS 96.4% and 60.7% VS 85.7% respectively in the VS combined group of control group 14.3% VS was 39.3% , the difference was statistically significant between the two groups of PFS(P＜0. 05), the control group was （4.55±0.41）months and the combined group was （6.99±0.60）months, (P＜0. 05) was no significant difference in the quality of life score between the two groups.There was no significant difference between the control group and the combined group before treatment. After treatment, the control group was higher than the combined group, and the difference was statistically significant. Conclusion: Although the addition and subtraction of Yiqi Huayu Jiedu prescription can not reduce the sorafenidin.Side effects, but Yiqi Huayu Jiedu prescription combined with Solafenil can prolong the survival rate of six months, one year and two years, at the same time it can prolong the patients' disease survival time without progress and improve the patients' quality of life.

参考文献/References:

[1] Taketomi A, Fukuhara T, Morita K, et al. Improved Results of a Surgical Resection for the Recurrence of Hepatocellular Carcinoma After Living Donor Liver Transplantation[J] . Annals of Surgical Oncology, 2010, 17(9):22832289.
[2] 吕桂帅,陈 磊,王红阳.我国肝癌研究的现状与前景[J] .生命科学,2015, 27(3):237248.
[3] 吴文卓,贺松其.补气化瘀方对原发性肝癌癌痛患者生活质量的影响[J] .陕西中医, 2017,38(9):11961198.
[4] 宋振民,李 慧,强亚杰,等.沙参麦冬汤加减联合GP化疗治疗晚期非小细胞肺癌疗效研究[J] . 陕西中医, 2018，39(4)：224226.
[5] 李 静,钱彦方,李秀玉, 等.肿瘤早期姑息医学与中医抗肿瘤模式的探讨[J] .世界中医药,2016,11(2):368371.
[6] 曾普华,郜文辉,潘敏求,等.益气化瘀解毒方对人肝癌裸鼠HepG2移植瘤MVD、HIF1a、VEGF/KDR表达的影响[J] .中华中医药学刊, 2014，35(7):15631565.
[7] 曾普华,郜文辉,潘敏求,等.益气化瘀解毒方及拆方对人肝癌HepG2裸鼠移植瘤和HIF1α、Ecad表达的影响[J] .辽宁中医杂志, 2014,32(9):20042006.
[8] 郜文辉，曾普华，潘敏求，等.益气化瘀解毒方含药血清对鸡胚尿囊膜血管生成的影响[J] .中华中医药学刊，2013，31（1）：1920.
[9] 曾普华，郜文辉，潘敏求，等.益气化瘀解毒方药对人肝癌HepG2细胞增殖和裸鼠移植瘤生长的影响[J] .现代肿瘤医学，2014，22（1）：811.〖ZK)〗
[10] 安海燕,林俊豪,孙海涛,等.鳖甲煎丸通过RhoA/ROCK信号通路抑制肝癌细胞血管形成拟态的生成[J] .南方医科大学学报,2018,29(8):9971001.

相似文献/References:

[1]杨禹娟,张勇,吕军,等.益气复脉注射液治疗老年冠心病并发慢性心力衰竭30例[J].陕西中医,2016,(10):1325.
　Yang Yujuan,Zhang Yong,Lv Jun,et al.[J].,2016,(3):1325.
[2]景中民,朱海松,徐海亮,等.前列舒通胶囊联合盐酸坦索罗辛胶囊治疗湿热瘀阻型前列腺炎临床研究*[J].陕西中医,2019,(3):294.
　JING Zhongmin,ZHU Haisong,XU Hailiang,et al.Clinical reserach of Qianlie Shutong capsule combined with tamsulosin hydrochloride capsule in treating dampheat stagnation prostatitis[J].,2019,(3):294.
[3]马素红,李 游,郑维波.桑菊饮加减方治疗感染后咳嗽风热阴伤证临床研究*[J].陕西中医,2019,(3):315.
　MA Suhong,LI You,ZHENG Weibo..Clinical effect of Sangju Yin Jiajian in treating postinfection cough Fengre Shangyin syndrome[J].,2019,(3):315.
[4]张 琳,高 勇.复方红豆杉胶囊对Walker256移植性肝癌大鼠HIF1α、 VEGF及PCNA表达的影响*[J].陕西中医,2019,(2):148.
　ZHANG Lin,GAO Yong..The effects of Fufang Hongdoushan capsule in the expression of HIF1α， VEGF and PCNA in Walker256 transplanted liver cancer rats[J].,2019,(3):148.
[5]陈 晨.补阳还五汤对急性脑梗死患者血管内皮生长因子、血管生成素2及神经功能影响的研究*[J].陕西中医,2019,(1):28.
[6]张连生,王月田,张志洋.针刺、西替利嗪联合曲安奈德喷雾剂治疗变应性鼻炎疗效 及对患者RQLQ评分、slgE、血清炎症因子的影响*[J].陕西中医,2019,(4):534.
[7]全 健,丁文涛 Δ,武 辉.穴位注射配合桂枝芍药知母汤加减治疗类风湿性关节炎临床研究[J].陕西中医,2019,(5):671.
　QUAN Jian,DING Wentao,WU Hui..Rheumatoid arthritis treated by acupoint injection combined with Guizhi Shaoyao Zhimu decoction[J].,2019,(3):671.
[8]杨宏升.安胃活血汤联合序贯法治疗慢性萎缩性胃炎胃癌前病变疗效研究[J].陕西中医,2019,(9):1195.
　YANG Hongsheng..Effect of Anwei Huoxue decoction combined with sequential therapy on gastric precancerous lesions of chronic atrophic gastritis[J].,2019,(3):1195.
[9]戴凤翔,邱联群△.当归四逆汤联合灸法治疗类风湿性关节炎临床研究[J].陕西中医,2019,(9):1235.
[10]樵书宏,寇鹏涛,郭娟莉,等.桃红四物汤联合普瑞巴林治疗带状疱疹后遗神经痛疗效及机制研究*[J].陕西中医,2019,(9):1251.
　QIAO Shuhong,KOU Pengtao,GUO Juanli,et al.Efficacy and mechanism of Taohong Siwu decoction combined with pregabalin in the treatment of postherpetic neuralgia[J].,2019,(3):1251.

备注/Memo

备注/Memo:
*国家自然科学基金资助项目（81603603） 湖南省科技计划项目（2016SK2051） 湖南省教育厅优秀青年项目（14B135） 湖南中医药大学研究生创新课题（2017CX21）
更新日期/Last Update: 2019-03-13